Market Research Reports, Inc.

Global Polyethylene Teraphthalate Market Is Expected to Reach $65.4 Billion by 2022; Finds New Report

LogoGlobal Polyethylene Teraphthalate Market is valued at $36.13 billion in 2015 and is expected to reach $65.4 billion by 2022 growing at a CAGR of 8.84% between 2015 and 2022. Rising demand of polyethylene teraphthalate from food and beverage sector, increasing demand for packaged food, rise in demand for electronics and automotive applications and eco friendly substitution are the major driving factors of the market. Furthermore, factors such as rapid urbanization, innovative packaging and high economic growth are favoring the market. However, factors such as growing environmental concerns and strict regulations imposed by governments are hampering the growth of the market. Moreover, economic fluctuations and volatility of crude oil prices is also likely to hinder the market.

Railway Infrastructure Spending Market in Saudi Arabia to Grow at a CAGR of 7.88% During the Period 2016-2020; Finds New Report

LogoReport forecast the railway infrastructure spending market in Saudi Arabia to grow at a CAGR of 7.88% during the period 2016-2020.

Global Pastas and Noodles Market to Grow at a CAGR of 3.73% During the Period 2016 - 2020.; Finds New Report

LogoReport forecast the Global Pastas and Noodles Market to grow at a CAGR of 3.73% during the period 2016-2020.

Global Archery Equipment Market to Grow at a CAGR of 6.91% During the Period 2016 - 2020; Finds New Report

LogoMarket Research Reports, Inc. has announced the addition of “Global Archery Equipment Market 2016 - 2020” research report to their website www.MarketResearchReports.com

South Korea, Spain and Vietnam Tourism Report Q2 2016; New Report Launched

LogoSouth Korea's tourism market will continue to grow healthily in the next five years, despite initial fears that the MERS outbreak of May 2015 may damage it. The government is promoting effectively a tourism market that caters well for both leisure holidays and business travellers (MICE) in search for tourist attractions in between conferences. Along with the approaching 2018 Winter Olympics, these should create significant opportunities for the development of the hotel sector, which remains under-developed to this day. Meanwhile, the increase in the number of tourist arrivals, especially from the Asia Pacific, will continue to drive up international tourism receipts value.

Vascular Closure Global Market Is Value Expected to Reach $1,665.2 Million by 2022; Finds New Report

LogoVascular closure is a procedure done for the closure of the punctured arterial wall after the performance of the catheterization procedure using the active and passive approximators. The active and passive approximators are the vascular closure device that reduce the blood loss with better haemostasis and reduce the time of ambulation with an increase the patient comfort. They are designed to provide quick and reliable haemostasis of access site after the invasive catheterization procedure. They were introduced in the 1990's to overcome the complications caused by the manual compression. The vascular closure global market is valued at $XX million in 2015 and expected to grow at a high single digit CAGR to reach $1,665.2 million by 2022. The vascular closure devices global market is segmented by product type, access, intervention and geography.

Asia-Pacific Type 2 Diabetes Mellitus Treatment Market Will Exceed $10 Billion by 2021; Finds New Report

LogoThe treatment market for Type 2 Diabetes Mellitus (T2DM) in the Asia-Pacific (APAC) region will increase from a little under $6.1 billion in 2014 to just over $10 billion by 2021, at a Compound Annual Growth Rate (CAGR) of 7.7%, according to new research.

Structural Heart Devices Global Market Is Value Grow at a CAGR to Reach $8,792.0 Million by 2022; Finds New Report

LogoStructural heart devices has emerged as a new focus area of medical device manufacturers as the population of most developed and developing countries continue to become older and risk of cardiovascular diseases increase with aging. The cardiovascular diseases which also include structural heart diseases have become leading cause of death. It is projected that, with newfound prosperity due to globalization and industrialization has led to changing lifestyle increasing risk of younger people developing cardiovascular diseases. The increased interest has led to development of new technologies and devices that are less invasive and address the need of treatment of patients who are considered too weak to withstand the trauma of an open heart surgery.

Short Bowel Syndrome Market Volume Is Estimated to 2.67 Billion by 2020; Finds New Report

LogoShort Bowel Syndrome - Market Insights, Epidemiology and Market Size Forecast-2020 Reports provides an overview of the disease and global market size of the Short Bowel Syndrome for the 7MM (United States, EU5 (France, Germany, Italy, Spain and UK) and Japan). It also includes global historical and forecasted epidemiological data for the diagnosed incident cases of Short Bowel Syndrome from 2010-2020.

Rheumatoid Arthritis (RA) - Market Insights, Epidemiology and Market Size Forecast - 2020; New Report Launched

LogoRheumatoid Arthritis (RA) - Market Insights, Epidemiology and Market Size Forecast-2020" Reports provides an overview of the disease and global market size of the Rheumatoid Arthritis (RA) for the United States, EU5 (France, Germany, Italy, Spain, UK) and Japan. It also includes global historical and forecasted epidemiological data for the diagnosed incident cases of Rheumatoid Arthritis (RA) from 2010-2020.Rheumatoid arthritis is an autoimmune disease in which the body's immune system – which normally protects its health by attacking foreign substances like bacteria and viruses – mistakenly attacks the joints. RA affects between 0.5 and 1% of adults in the developed world with between 5 and 50 per 100,000 people newly developing the condition each year. RA reduces lifespan on average from three to twelve years. It is unknown how these agents compare to the current biologics because there are no head-to-head trials to date. Most studies are conducted on patients who have already failed current therapy, suggesting that the likely niche for these newer pipeline agents may be for RA that is more severe.